About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 196012, 5 pages
http://dx.doi.org/10.1155/2013/196012
Clinical Study

Pediatric Inflammatory Bowel Disease with Cytoplasmic Staining of Antineutrophil Cytoplasmic Antibodies

1Division of Pediatric Gastroenterology, Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, P.O. Box 80215, Jeddah 21589, Saudi Arabia
2Department of Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, P.O. Box 80215, Jeddah 21589, Saudi Arabia

Received 6 November 2012; Accepted 17 January 2013

Academic Editor: G. Opdenakker

Copyright © 2013 Omar I. Saadah and Jamil A. Al-Mughales. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Peeters, S. Joossens, S. Vermeire, R. Vlietinck, X. Bossuyt, and P. Rutgeerts, “Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease,” American Journal of Gastroenterology, vol. 96, no. 3, pp. 730–734, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Papp, I. Altorjay, G. L. Norman, and P. L. Lakatos, “Utility of serological markers in inflammatory bowel diseases: gadget or magic?” World Journal of Gastroenterology, vol. 13, no. 14, pp. 2028–2036, 2007. View at Scopus
  3. X. Bossuyt, “Serologic markers in inflammatory bowel disease,” Clinical Chemistry, vol. 52, no. 2, pp. 171–181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Ferrante, L. Henckaerts, M. Joossens et al., “New serological markers in inflammatory bowel disease are associated with complicated disease behaviour,” Gut, vol. 56, no. 10, pp. 1394–1403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. H. J. Freeman, “Inflammatory bowel disease with cytoplasmic-staining antineutrophil cytoplasmic antibody and extensive colitis,” Canadian Journal of Gastroenterology, vol. 12, no. 4, pp. 279–282, 1998. View at Scopus
  6. J. C. Escher, “Inflammatory bowel disease in children and adolescents: recommendations for diagnosis—the Porto criteria,” Journal of Pediatric Gastroenterology and Nutrition, vol. 41, no. 1, pp. 1–7, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Bousvaros, D. A. Antonioli, R. B. Colletti et al., “Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America,” Journal of Pediatric Gastroenterology and Nutrition, vol. 44, no. 5, pp. 653–674, 2007.
  8. J. Satsangi, M. S. Silverberg, S. Vermeire, and J. F. Colombel, “The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications,” Gut, vol. 55, no. 6, pp. 749–753, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Gasche, J. Scholmerich, J. Brynskov et al., “A simple classification of Crohn's disease: report of the working party for the world congresses of gastroenterology, Vienna 1998,” Inflammatory Bowel Diseases, vol. 6, no. 1, pp. 8–15, 2000. View at Scopus
  10. P. Rutgeerts, W. J. Sandborn, B. G. Feagan et al., “Infliximab for induction and maintenance therapy for ulcerative colitis,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2462–2476, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Savige, D. Gillis, E. Benson et al., “International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA),” American Journal of Clinical Pathology, vol. 111, no. 4, pp. 507–513, 1999. View at Scopus
  12. J. A. Goeken, “AntiNeutrophil cytoplasmic antibody—a useful serological marker for vasculitis,” Journal of Clinical Immunology, vol. 11, no. 4, pp. 161–174, 1991. View at Scopus
  13. J. Ludemann, B. Utecht, and W. L. Gross, “Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme,” Journal of Experimental Medicine, vol. 171, no. 1, pp. 357–362, 1990. View at Publisher · View at Google Scholar · View at Scopus
  14. R. C. W. Wong, R. A. Silvestrini, J. A. Savige, D. A. Fulcher, and E. M. Benson, “Diagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns,” Journal of Clinical Pathology, vol. 52, no. 2, pp. 124–128, 1999. View at Scopus
  15. C. E. M. Rodrigues, M. R. M. Callado, C. A. Nobre et al., “Wegener's granulomatosis: prevalence of the initial clinical manifestations-report of six cases and review of the literature,” Revista Brasileira de Reumatologia, vol. 50, no. 2, pp. 157–164, 2010. View at Scopus
  16. J. D. Akikusa, R. Schneider, E. A. Harvey et al., “Clinical features and outcome of pediatric Wegener's granulomatosis,” Arthritis Care and Research, vol. 57, no. 5, pp. 837–844, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. J. Haworth and C. D. Pusey, “Severe intestinal involvement in Wegener's granulomatosis,” Gut, vol. 25, no. 11, pp. 1296–1300, 1984. View at Scopus
  18. E. W. Walton, “Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis),” British Medical Journal, vol. 2, no. 5091, pp. 265–270, 1958. View at Scopus
  19. S. Akbulut, “Multiple ileal perforations in a patient with Wegener's granulomatosis: a case report and literature review,” Journal of Gastrointestinal Surgery, vol. 16, no. 4, pp. 857–862, 2012. View at Publisher · View at Google Scholar
  20. A. C. Yildirim, E. Koçak, P. Yildiz et al., “Multiple intestinal perforation in a patient with Wegener's granulomatosis: a case report and review of the literature,” Gastroenterologie Clinique et Biologique, vol. 34, no. 12, pp. 712–715, 2010. View at Publisher · View at Google Scholar · View at Scopus